NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.

Xin XuWei HuangAndras A HeczeyDaofeng LiuLinjie GuoMichael WoodJingling JinAmy N CourtneyBin LiuErica J Di PierroJohn HicksGabriel A BarraganHo NgaiYuhui ChenBarbara SavoldoGianpietro DottiLeonid S Metelitsa

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our results informed selection of the CD28-based GD2.CAR.15 construct for clinical testing and led to initiation of a first-in-human CAR-NKT cell clinical trial (NCT03294954).

Keyphrases

clinical trial
induced apoptosis
endothelial cells
cell cycle arrest
single cell
cell therapy
induced pluripotent stem cells
open label
study protocol
randomized controlled trial
double blind
cell proliferation
nk cells
phase iii
light emitting